First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma

Kim R.D.Sarker D.Meyer T.Yau T.Macarulla T.Park J.-W.Choo S.P.Hollebecque A.Sung M.W.Lim H.-Y.Mazzaferro V.Trojan J.Zhu A.X.Yoon J.-H.Sharma S.ZHONG-ZHE LINChan S.L.Faivre S.Feun L.G.Yen C.-J.Dufour J.-F.Palmer D.H.Llovet J.M.Manoogian M.Tugnait M.Stransky N.Hagel M.Kohl N.E.Lengauer C.Sherwin C.A.Schmidt-Kittler O.Hoeflich K.P.Shi H.Wolf B.B.Kang Y.-K.2022-06-102022-06-1020192159-8274https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075943998&doi=10.1158%2f2159-8290.CD-19-0555&partnerID=40&md5=6ae9258a7fde1efd3ed825e0be1be41dhttps://scholars.lib.ntu.edu.tw/handle/123456789/612552First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinomajournal article10.1158/2159-8290.CD-19-0555315755412-s2.0-85075943998